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actor VII (FVII) is found in small amounts in plasma and has
 very short half-life in circulation.
FVII is vitamin K-dependently synthesized in the liver. As
uch, hepatopathies, vitamin K deﬁciency, or use of vitamin K
ntagonists is the cause of acquired deﬁciency. Other types of
cquired FVII deﬁciencies are rare.1 Here we describe a case
f acquired factor VII deﬁciency associated to the presence of
upus anticoagulant.
ase  report
 36-year-old black male patient was hospitalized in March
013 after a four-day period of low back pain, bruised hips,
acroscopic hematuria, and gingival bleeding. At admission,
e was conscious, oriented, pale, and tachycardic (108 beats
er minute), with a blood pressure of 120/90 mmHg, mild
dema, and varicose veins of the lower limbs. In addition,
hronic malleolar ulcers were observed, with signs of bleed-
ng and bruising in the pelvic region. The patient denied any
ersonal or family history of bleeding diathesis. Renal and
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eserved.urological diseases were also ruled out. Additional examina-
tions revealed a hemoglobin level of 4.8 g/dL, platelet count of
270 × 109/L, and incoagulable blood based on the prothrombin
time (PT) and activated partial thromboplastin time (APTT).
The patient received a transfusion of red blood cells, cryopre-
cipitate and fresh frozen plasma. He was then transferred to
the intensive care unit. Two days later, the patient still pre-
sented with hematuria, ecchymosis, and incoagulable blood
according to PT, with patient-to-control APTT ratio of 1.79.
Thus, transfusion support was continued. The patient had
positive results for lupus anticoagulant antibodies and nega-
tive results for anticardiolipin immunoglobulin (Ig)M, IgG and
IgA antibodies, as well as antinuclear and rheumatoid fac-
tors. The activity levels of the coagulation factors were 3%,
130%, 150%, >200%, 47%, and 75.8% for factors VII, II, V, VIII,
IX and X, respectively. We  chose to start intravenous pulse
therapy with methylprednisolone and administer a prothrom-
bin complex concentrate for persistent bleeding. The patient
recovered well, with no bleeding after the administration
of the prothrombin complex concentrate and corticotherapy.
Corticotherapy was maintained with the oral administration, MG, Brazil.
of 1 mg/kg/day prednisone. The patient was discharged after
17 days of hospitalization and referred for follow-up in an out-
patient clinic. The corticoid dose was reduced after monitoring
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Table 1 – Evolution of tests over eight months.
Initial After 8
months
PT (%)
(RV: 70–100)
Incoagulable 83.2
APTT (P/C ratio)
(RV: 0.9–1.25)
Incoagulable 1.05
Fibrinogen (mg/dL)
(RV: 200–400)
396  248.7
Factor II (%)
(RV: 70–120)
130  130
Factor V (%)
(RV: 70–120)
180  180
Factor VII (%)
(RV: 60–140)
3  60.6
Factor VIII (%)
(RV: 50–150)
>200 >200
Factor IX (%)
(RV: 50–150)
47  47
Factor X (%)
(RV: 70–150)
75.8  75.8
Lupus anticoagulant Positive Negative
PT: prothrombin time; APTT: activated partial thromboplastin time;
No consensus has been reached regarding the treatment ofRV: reference value; P/C ratio: patient/control ratio.
in the clinic, and consecutive PT test results showed a pro-
gressive tendency toward normality. The patient’s condition
stabilized, without new hemorrhagic episodes. The corticoid
treatment was suspended six months after the initial adminis-
tration. Two months after, the PT was 83.2%, patient-to-control
APTT ratio was 1.05, ﬁbrinogen level was 248.7 mg/dL and FVII
activity level was 60.6%.
Table 1 shows the evolution of the main tests from
hospitalization to two months after the discontinuation of
corticosteroids.
Discussion
Hereditary coagulation factor deﬁciencies, except hemophilia,
are autosomal recessive hereditary diseases, with incidences
ranging from one case in 500,000 to one case in two million
people.2 Thus, they are considered rare coagulopathies. The
suspected diagnosis is conﬁrmed using prolonged PT and/or
APTT, thereby suggesting the need for further evaluations.
Among the rare congenital factor deﬁciencies, FVII deﬁciency
is the most common.2 The clinical manifestations of this
condition range from asymptomatic to severe hemorrhagic
disorders, although the most common bleeding sites are the
skin and mucosae.3
Acquired FVII deﬁciency, which is not associated with vita-
min K deﬁciency, antagonists or hepatopathies, though rare,
is correlated with the presence of different tumors,1,4 the
occurrence of sepsis,5 antiphospholipid antibodies,6 aplastic
anemia7 and hematopoietic stem cell transplantation.8
Coagulation inhibitors are abnormal endogenous com-
pounds that inhibit blood coagulation. Most of these inhibitors
are antibodies that partially or completely neutralize the acti-
vation or function of a speciﬁc coagulation factor, but they
can also interfere with interactions between several factors. 2 0 1 5;3  7(4):269–271
In most cases, these antibodies lead to deﬁciency of a speciﬁc
factor due to increased peripheral clearance.6
The presence of lupus anticoagulant was originally iden-
tiﬁed in association with systemic lupus erythematosus but
is currently described as associated with other inﬂammatory
and benign diseases, as well as in healthy individuals without
any apparent underlying disease.9 In vitro, lupus anticoagulant
is associated with prolonged APTT and rarely to prolonged PT.
In vivo, the situation is different and it is strongly associated
with arterial and venous thromboses and rarely with bleeding.
However, the presence of lupus anticoagulant may also be
associated with antibodies against FVII, resulting in severe
hemorrhagic diathesis. In a study of 33 patients presenting
with antiphospholipid syndrome, Bidot et al.10 reported that
67% of the patients had low FVII levels.
There are reports of acquired FVII deﬁciency associ-
ated with different clinical conditions. Granger and Gidvani1
described a case of FVII deﬁciency in association with Wilms’
tumor in a 2-year-old child, and Fatimi et al.4 reported a
64-year-old patient with isolated prolonged PT, severe reduc-
tions in FVII activity, and a giant right atrial myxoma. After
the surgical removal of the myxoma, the PT normalized and
the FVII activity level increased within the ﬁrst 24 h after
surgery. Bidet et al.5 described a 24-year-old patient with
intra-abdominal septic focus who developed FVII deﬁciency,
without evidence of inhibitors; the deﬁciency partially recov-
ered only with the intravenous administration of vitamin K.
With the resolution of sepsis, the patient’s PT and FVII activ-
ity normalized. Lim et al.6 reported a 71-year-old patient with
an expanding hematoma of the thoracic and abdominal walls,
and prolonged APTT and PT. Additional examinations revealed
a potent lupus anticoagulant and reduced levels of multiple
coagulation factors.
It is noteworthy that, in the current case, the prolonged PT
may be related to the factor VII deﬁciency and the prolonged
APTT to the presence of lupus anticoagulant, but it is pos-
sible that high levels of lupus anticoagulant can affect both
PT and APTT6,11 and, although rare, the titers may be reduced
or even normalized with immunosuppressive therapy.11 How-
ever, the paradoxical effect of thrombotic tendency should be
remembered in the presence of lupus anticoagulant in vivo
as there are reports of thrombotic complications due to the
treatment of secondary bleeding using prothrombin complex
concentrates and recombinant activated FVII in the presence
of lupus anticoagulants.12,13
This patient did not present thrombotic complications sec-
ondary to the treatment instituted and, although he had a
history of venous insufﬁciency and chronic malleolar ulcers,
there is no evidence of current or previous venous throm-
boembolism. So the diagnostic criteria for antiphospholipid
syndrome should not be closed because, despite having pos-
itive lupus anticoagulant test results, there are no clinical
criteria, namely: (1) arterial, venous or small vessel thrombosis
occurring in any tissue or (2) miscarriages in women.14
Isolated acquired FVII deﬁciency is rare, and its phys-
iopathological mechanism is sometimes difﬁcult to elucidate.secondary bleeding in such conditions. Antiﬁbrinolytic agents,
fresh frozen plasma, and prothrombin complex, as well as
recombinant activated FVII (rFVIIa) concentrates, have been
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sed depending on the severity of bleeding and their avail-
bility in each institution. Some reports describe the use of
mmunomodulatory therapies, with varying success depend-
ng on individual patients. Noteworthy was the successful use
f rFVIIa to control acquired and congenital FVII deﬁciency-
nduced bleeding, which was administered in repeated doses
ntil the risk of hemorrhage was eliminated.12,13,15
Although the presence of a lupus anticoagulant is often
elated to thrombotic events, in this study, we  describe a
atient with an associated bleeding disorder. During treat-
ent, the patient did not present other symptoms that
ustiﬁed FVII deﬁciency. As we  have observed, lupus anticoag-
lant may also develop in normal individuals. This case study
as based on the administration and subsequent discontin-
ation of high doses of corticoids, and the administration of
rothrombin complex concentrates to control acute bleeding.
he clinical course of the patient was satisfactory.
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